Skip to main content Skip to main navigation Skip to search
Home

Top navigation main

  • News & media
  • Jobs
  • Ministers
  • Contact us
Main menu

AWE Main

  • Agriculture and land
    Agriculture and land Building stronger and more sustainable agriculture, fisheries, forestry and land care.
    • Animal health
    • Climate change and agriculture
    • Drought, disaster and rural support
    • Farming, food and drought
    • Fisheries
    • Forestry
    • Levies and charges on agricultural products
    • Mouse infestation advice
    • Plant health
    Xylella

    Protect against unwanted plant pests

    Our biosecurity system helps protects us. Everyone has a role in supporting our biosecurity system.

    Find out more

  • Biosecurity and trade
    Biosecurity and trade
    • Aircraft, vessels and military
    • Biosecurity policy
    • Cats and dogs
    • Exporting
    • Importing
    • Pests, diseases and weeds
    • Public awareness and education
    • Trade and market access
    • Travelling or sending goods to Australia
    • Report a concern
    Brown marmorated stink bug

    BMSB Seasonal Measures

    Australia has strengthened seasonal measures to manage the risk of BMSB.

    View our seasonal measures

  • Science and research
    Science and research Undertaking research and collecting data to support informed decisions and policies.
    • Australian Bureau of Agricultural and Resource Economics and Sciences (ABARES)
    • Plant Innovation Centre
    Abares

    ABARES Insights

    Get 'snapshots’ of agricultural, forestry and fisheries industries, or analysis of key issues.

    Find out more

  • About us
    About us We enhance our agricultural industries and trade, and manage the threat of biosecurity risks to Australia.
    • Accountability and reporting
    • Assistance, grants and tenders
    • Contact us
    • Fees and charges
    • News and media
    • Our commitment to you
    • Payments
    • People and jobs
    • Publications
    • What we do
    • Who we are
    Budget 2025-26

    Budget 2025-26

    The 2025–26 Portfolio Budget Statements were released on 25 March 2025.

    Find out more

  • Online services
    Online services We do business with you using online platforms. This makes it easier for you to meet your legal requirements.
Department of Agriculture

Breadcrumb

  1. Home
  2. Biosecurity and trade
  3. Pests, diseases and weeds
  4. Animal pests and diseases
  5. Ehrlichiosis in dogs
  6. Ehrlichiosis: additional veterinary guidelines for managing CME in Australia

Sidebar first - Pests diseases weeds

  • Ehrlichiosis in dogs
    • Guidelines for dog owners
    • Veterinary guidelines
    • Dog rescue and rehoming
    • Travelling with your dog in Australia
    • Ehrlichiosis resources

Ehrlichiosis: additional veterinary guidelines for managing CME in Australia

Canine monocytic ehrlichiosis (CME), commonly known simply as ehrlichiosis, is a tick-borne disease of dogs caused by infection with the bacterium Ehrlichia canis. In Australia, dogs can be infected with E.canis within hours after being bitten by an infected brown dog tick (Rhipicephalus linnaei; tropical lineage of R.sanguineus), a species that is habituated to human settlements and built environments. E.canis occurs worldwide, particularly in tropical and subtropical regions.

The first detection of ehrlichiosis in Australia was in May 2020. Since then, it has been diagnosed in dogs in the northern regions of Western Australia and South Australia, all of the Northern Territory, and north-western Queensland. Ehrlichiosis is a notifiable disease and must be reported to state or territory biosecurity authorities according to jurisdictional requirements. This may include reporting via the Emergency Animal Disease hotline (1800 675 888).

E.canis is an obligate intracellular, rickettsia-like bacterium that infects monocytes and may sequester in haematopoietic tissues. It causes severe and potentially life-threatening disease, with a range of nonspecific clinical signs in both acute and chronic forms. No vaccine is available.

This page provides information in addition to the national veterinary guide to ehrlichiosis, and offers additional insights around the challenges and ethical considerations of managing infected dogs in Australia.

Acute ehrlichiosis

Some dogs are diagnosed in the acute stage, which has an incubation period of 1 to 3 weeks. Depending on access to veterinary services, dogs may be treated and appear to recover, but there is no straightforward test to monitor treatment success.

A positive PCR test post-treatment may indicate that the dog is still bacteraemic and treatment was unsuccessful. Given the ability of the organism to sequester in tissues, and be undetectable in circulation, a negative result does not indicate that the dog has successfully cleared the infection. Similarly, use of nonquantitative ELISA serology after treatment is of limited value. This is because antibody titres (that are non-protective) may remain detectable for months to years after treatment. Aspirates of the spleen and bone marrow may detect the organism in subclinical cases, but this is a risky procedure, particularly in a thrombocytopenic dog. For these reasons, consider any dog diagnosed with E.canis infection as potentially subclinically infected for life. Educate owners about the clinical signs of chronic disease, the need to protect in-contact dogs from infection and the importance of limiting disease spread.

Subclinical ehrlichiosis

Some dogs may be infected but show no clinical signs. Post-infection, they may clear the organism from circulation, or may become subclinical carriers of the bacteria in the spleen and bone marrow for months or years. These dogs may not present to veterinarians unless the disease progresses to its chronic form. There are particular challenges around the long-term management of subclinically infected and post-acute patients:

  • The proportion of subclinically infected dogs that go on to develop chronic, end-stage disease is currently unknown.
  • Dogs that have lived or travelled in regions where E.canis–infected ticks exist may become subclinically infected without their owners’ knowledge, and go on to develop chronic ehrlichiosis months or years later. Because of the time delay, the connection between travel and clinical signs may not be obvious.
  • Interstate movement of infected dogs, associated with travel or rehoming, into areas where brown dog ticks exist but E.canis is not known to be active occurs regularly, and some of these dogs will develop chronic disease.
  • Some jurisdictions place a biosecurity obligation on responsible parties to minimise the risk of spread, but there is no obligation for individuals or rehoming groups to disclose the health status of infected dogs to adopting new owners.
  • The clinical and geographical/movement history of dogs adopted either privately or through rehoming and rescue organisations may not always be made clear to new owners or treating veterinarians. The situation is further complicated if interstate rehoming involves multiple changes in dog ownership.

Not knowing that a dog is subclinically infected can result in delayed diagnosis or misdiagnosis, particularly if veterinarians in areas where E.canis is not known to be active are not on the lookout for possible infections. Chronic ehrlichiosis mimics other diseases and can be difficult or impossible to treat. The absence of an accurate diagnosis can lead to expensive testing that does not result in a diagnosis, ineffective treatment interventions and development of animal welfare issues.

Stringent use of a repel-and-kill tick product for dogs that live in or travel through brown dog tick–infested areas of Australia affords the best protection against tick attachment. To prevent transmission, dogs with suspected or confirmed ehrlichiosis that live in an area where the brown dog tick is likely to exist need lifelong treatment with registered systemic tick control products, even where there is no visible tick burden. Dog owners should be informed of the future disease risk to other dogs in the household and local community if this protocol is not maintained. Consult the veterinary guide for suitable product suggestions.

Chronic ehrlichiosis

Veterinarians across Australia need to be aware of the risks and signs of chronic ehrlichiosis. Consider the disease as a differential diagnosis when severe, nonresponsive illness or haematological abnormalities occur in any dog that has travelled to, or possibly originated from, a region with E.canis–infected brown dog ticks. History taking should include questions about movements, E.canis testing, treatment and tick control. Consult the map in the veterinary guide to see where brown dog ticks are likely to exist in Australia.

Preoperative complete blood counts (CBCs) for healthy but suspect dogs may assist in detection of chronic ehrlichiosis. Suspect dogs are any that:

  • live in a brown dog tick–infested area, or a region where E.canis is known or likely to be active
  • have an unknown movement history
  • have an unknown or poor tick control history
  • live or have lived with a confirmed case of ehrlichiosis
  • have previously been diagnosed with ehrlichiosis, whether they were treated or not.

Routine CBCs sometimes aid in detection of subclinical cases, which can show marginal thrombocytopenia and/or other haematological abnormalities in clinically normal dogs, leading to submission of samples for E.canis exclusion.

Clinical signs of chronic ehrlichiosis are associated with laboratory abnormalities of increasing severity and tend to be terminal in their outcome. As the infection progresses, a range of immune complex pathologies, including vasculitis, uveitis and glomerulonephritis, develop because of excessive immunoglobulin production. However, these antibodies are nonprotective. Terminal bone marrow failure is associated with pancytopenia and, frequently, sepsis. Clinical presentations include all of the signs seen in the acute phase. Dogs may present with fever, lethargy, and severe, rapid wasting, even with apparently adequate nutrition. Clinical signs are wide-ranging, and may include epistaxis, petechiae/ecchymoses, dyspnoea, harsh lung sounds, lymphadenopathy and splenomegaly. Uveitis, intraocular bleeding and corneal oedema are common. Many dogs present with shifting lameness, polyarthritis and vasculitis-associated dependent oedema. Infected dogs are more susceptible to secondary infections and may present with nonhealing wounds, persistent bleeding from injuries and surgical incisions, treatment-resistant infections or treatment failures. Blood tests often show severe thrombocytopenia, leukopenia and anaemia, progressing to nonregenerative pancytopenia. This form of the disease is usually fatal, and treatment efforts are likely to be futile. Images of some typical presentations are in the veterinary guide.

Treatment and prognostic indicators

Treat both acute and chronic infections with doxycycline 10 mg/kg daily for 28 days. Most other antibiotics are ineffective against E.canis. However, there is evidence that rifampicin used at 15 mg/kg PO every 12 hours for 7 days may be a suitable choice, but only if doxycycline fails to clear infection. Under current guidelines for antimicrobial stewardship, rifampicin is not registered for use in animals, and should not be used off-label, except in exceptional circumstances for individual animals with laboratory-confirmed, persistent E.canis infection.

Immunocomplex pathology that causes significant morbidity can be palliated with a 7 to 10 day course of prednisolone at an anti-inflammatory dose (1 mg/kg PO every 24 hours). This appears to help reduce complications. However, treatment failure is common if the dog has progressed to complete pancytopenia. Make owners aware that chronic ehrlichiosis carries a grave prognosis, regardless of treatment intervention and effort.

Serial haematology is useful to assess disease progression. Dogs with chronic ehrlichiosis will present with a variety of haematological abnormalities, including:

  • thrombocytopenia (moderate to severe)
  • leukocytosis (acute) to leukopenia (chronic)
  • monocytosis
  • lymphocytosis (acute) to lymphopenia (chronic)
  • anaemia (mild to severe in late infection)
  • pancytopenia
  • hyperglobulinaemia
  • hypoalbuminaemia
  • elevations in liver enzymes
  • mild to moderate azotaemia.

Disease progression is associated with increasing severity of abnormality in haematological parameters. Timely euthanasia can be recommended on humane grounds when pancytopenia becomes evident.

Resources

Download and print our free ehrlichiosis materials and spread the word to dog owners about the dangers of ehrlichiosis.

General enquiries

Call 1800 900 090

Contact us online

Report a biosecurity concern

Thanks for your feedback.
Thanks! Your feedback has been submitted.

We aren't able to respond to your individual comments or questions.
To contact us directly phone us or submit an online inquiry

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Please verify that you are not a robot.

Skip
Page last updated: 27 July 2023

We acknowledge the continuous connection of First Nations Traditional Owners and Custodians to the lands, seas and waters of Australia. We recognise their care for and cultivation of Country. We pay respect to Elders past and present, and recognise their knowledge and contribution to the productivity, innovation and sustainability of Australia’s agriculture, fisheries and forestry industries.

Artwork: Protecting our Country, Growing our Future
© Amy Allerton, contemporary Aboriginal Artist of the Gumbaynggirr, Bundjalung and Gamilaroi nations.

Footer

  • Contact us
  • Accessibility
  • Disclaimer
  • Privacy
  • FOI

© Department of Agriculture, Fisheries and Forestry

Facebook X LinkedIn Instagram